Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): Results of the METIV-HCC phase III trial.
暂无分享，去创建一个
C. Porta | V. Mazzaferro | J. Bruix | A. Santoro | B. Daniele | L. Bolondi | L. Rimassa | V. Zagonel | E. Assenat | G. Abbadessa | P. Mathurin | M. Reig | M. Pracht | W. Harris | N. Damjanov | B. Schwartz | T. Goldberg | M. Lamar | M. Peck‐Radosavljevic | E. R. Caremoli